A novel approach to block HIV-1 coreceptor CXCR4 in non-toxic manner
Ye Liu1, Jieqiong Zhou, Ji-An Pan
1State Key Laboratory of Virology and Modern Virology Research Center, College of Life Sciences, Wuhan University, Wuhan, 430072, People's Republic of China.
Insights
This study introduces a novel method to reduce HIV-1 replication by modifying the CXCR4 coreceptor. The approach replaces natural CXCR4 with a mutant form, preserving function while blocking viral entry.
Area of Science:
- Molecular Biology
- Virology
- Immunology
Background:
- The chemokine receptor CXCR4 is a key coreceptor for human immunodeficiency virus type 1 (HIV-1) entry.
- RNA interference (RNAi) targeting CXCR4 is a potential HIV-1 therapeutic strategy, but risks impairing natural CXCR4 function.
- Loss of natural CXCR4 function can lead to undesirable side effects.
Purpose of the Study:
- To develop a novel therapeutic strategy for HIV-1 infection targeting the CXCR4 coreceptor.
- To create a method that reduces HIV-1 replication without compromising the essential natural functions of CXCR4.
- To evaluate the efficacy of a lentiviral vector expressing dual-shRNAs and an shRNA-resistant CXCR4 mutant.
Main Methods:
- Development of a single lentiviral vector system to simultaneously express CXCR4 dual-short hairpin RNAs (shRNAs) and an shRNA-resistant CXCR4 mutant (P191A).
- Utilized a 2A peptide-based strategy for recombinant lentiviral vector construction.
- Assessed the compensation of endogenous CXCR4 function and the reduction in HIV-1 replication.
Main Results:
- Successfully replaced endogenous CXCR4 with the P191A mutant, which compensated for the loss of natural CXCR4 functions.
- Achieved a significant reduction in HIV-1 replication by 59.2%.
- Demonstrated advantages of the 2A peptide strategy, including increased lentivirus titer and avoidance of promoter competition, over promoter-based strategies.
Conclusions:
- The novel approach effectively blocks HIV-1 coreceptor CXCR4 activity while preserving its normal physiological functions.
- This strategy offers a new therapeutic avenue for HIV-1 infection targeting CXCR4.
- The developed lentiviral vector system has potential universal applications for non-toxic knockdown of cellular proteins.
Abstract:
The chemokine receptor CXCR4 is one of the major coreceptors for human immunodeficiency virus type 1 (HIV-1) and considered as an important therapeutic target. Knockdown of CXCR4 by RNA interference has emerged as a promising strategy for combating HIV-1 infection. However, there is a potential drawback to this strategy as undesired side effects may occur due to the loss of natural function of CXCR4. In this study, we developed a novel approach using a single lentiviral vector to express simultaneously CXCR4 dual-shRNAs and an shRNA-resistant CXCR4 mutant possessing the most possible natural functions of CXCR4 and reduced HIV-1 coreceptor activity. Via this approach we achieved the replacement of endogenous CXCR4 by CXCR4 mutant P191A that could compensate the functional loss of endogenous CXCR4 and significant reduction of HIV-1 replication by 59.2 %. Besides, we demonstrated that construction of recombinant lentiviral vector using 2A peptide-based strategy has significant advantages over using additional promoter-based strategy, including increase of lentivirus titer and avoidance of promoter competition. Therefore, the novel approach to block HIV-1 coreceptor CXCR4 without impairing its normal function provides a new strategy for CXCR4-targeted therapeutics for HIV-1 infection and potential universal applications to knock down a cellular protein in non-toxic manner.
More Related Videos
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
01:10Retrovirus Life Cycles